MiBolsilloColombia on MSN7h
The SSA-1696 form: A Guide to Appointing a Representative for Social Security Matters
When dealing with the Social Security Administration (SSA), some beneficiaries may require the assistance of a representative ...
Iowa City Press-Citizen on MSN15h
State universities remove gender options from admissions forms, DEI references in strategic plans
Students will no longer be able to list their sex as anything other than “male” or “female” on state university admission ...
CAA Promotes 14 To Agent/Executive
CAA on Wednesday announced its promotion of 14 trainees from the agency’s Elevate program, including Oliver Acutt, Lianne ...
JD Supra1d
First Time Issuance of IRS Form for Elections Under Section 83(b)
For the first time, the IRS has issued an official form to be used for making an election under Section 83(b) of the Internal Revenue Code. Until ...
Here's how you can identify a fake ICE agent to avoid impostor scams
Though impersonating a federal agent is a crime, that has not stopped impostors from taking advantage. One of the most common ...
Aegon reports second half year 2024 results
Over the year, we remained disciplined in our management of capital. During the first half of 2024, we completed the EUR 1.535 billion share buyback program. In the second half, we completed a EUR 200 ...
manilatimes2d
Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
PharmiWeb2d
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...
PharmiWeb3d
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).